CN1882583A - 5－取代的咪唑 - Google Patents

5－取代的咪唑 Download PDF

Info

Publication number
CN1882583A
CN1882583A CNA2004800342361A CN200480034236A CN1882583A CN 1882583 A CN1882583 A CN 1882583A CN A2004800342361 A CNA2004800342361 A CN A2004800342361A CN 200480034236 A CN200480034236 A CN 200480034236A CN 1882583 A CN1882583 A CN 1882583A
Authority
CN
China
Prior art keywords
disease
compound
illness
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800342361A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·恩菲尔德
艾菲奥恩·菲利普斯
斯科特·思多纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1882583A publication Critical patent/CN1882583A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2004800342361A 2003-11-19 2004-11-15 5－取代的咪唑 Pending CN1882583A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0303076A SE0303076D0 (sv) 2003-11-19 2003-11-19 5-substituted imidazoles
SE03030764 2003-11-19

Publications (1)

Publication Number Publication Date
CN1882583A true CN1882583A (zh) 2006-12-20

Family

ID=29729100

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800342361A Pending CN1882583A (zh) 2003-11-19 2004-11-15 5－取代的咪唑

Country Status (13)

Country Link
US (1) US20080188518A1 (enExample)
EP (1) EP1687302A1 (enExample)
JP (1) JP2007511602A (enExample)
KR (1) KR20060117326A (enExample)
CN (1) CN1882583A (enExample)
AU (1) AU2004291456A1 (enExample)
BR (1) BRPI0416661A (enExample)
CA (1) CA2546093A1 (enExample)
IL (1) IL175440A0 (enExample)
NO (1) NO20062868L (enExample)
SE (1) SE0303076D0 (enExample)
WO (1) WO2005049611A1 (enExample)
ZA (1) ZA200604019B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008524212A (ja) * 2004-12-16 2008-07-10 アストラゼネカ・アクチエボラーグ ニコチン性アセチルコリン受容体リガンド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226000A (en) * 1987-09-10 1991-06-25 Merck Sharp & Dohme Oxadiazolyl-azabicycloheptanes and pharmaceutical compositions
WO2002015662A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
JP2004506734A (ja) * 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
FR2832713B1 (fr) * 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
EP1562945B1 (en) * 2002-11-11 2006-11-15 Neurosearch A/S 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof
SE0303075D0 (sv) * 2003-11-19 2003-11-19 Astrazeneca Ab 4-substituted imidazoles

Also Published As

Publication number Publication date
IL175440A0 (en) 2006-09-05
BRPI0416661A (pt) 2007-01-16
JP2007511602A (ja) 2007-05-10
US20080188518A1 (en) 2008-08-07
NO20062868L (no) 2006-08-21
WO2005049611A1 (en) 2005-06-02
SE0303076D0 (sv) 2003-11-19
KR20060117326A (ko) 2006-11-16
EP1687302A1 (en) 2006-08-09
CA2546093A1 (en) 2005-06-02
ZA200604019B (en) 2007-11-28
AU2004291456A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
RU2722149C1 (ru) Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
CN1132837C (zh) 螺呋喃并吡啶芳烷基胺、其制法和中间体及其药物组合物和制药用途
CN1675215A (zh) 作为烟碱性乙酰胆碱拮抗剂的芳基取代的二氮杂双环烷烃
CN1662542A (zh) 杂环化合物
CN1423651A (zh) 新的用途和新的n－氮杂双环－酰胺衍生物
CN1662541A (zh) 呋喃基化合物
CN1211983A (zh) 用于治疗的氨基甲酸的氮杂双环酯
CN1659170A (zh) 噻吩基化合物
JP2006507241A (ja) ニコチン性アセチルコリン作用剤としてのビアリールジアザビシクロアルカンアミド
CA2967153A1 (en) 6,7-dihydropyrazolo[1,5-.alpha.]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
CN103649019B (zh) 用于治疗精神分裂症的氘化的1-哌嗪子基-3-苯基-茚满
AU2015295301A1 (en) 6,7-dihydropyrazolo[1,5-alpha]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
RU2323218C2 (ru) Новые производные 1,4-диазабициклоалкана и фармацевтическая композиция на их основе
CA2954218A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
EP3592740B1 (en) Cyclic substituted imidazo[4,5-c]quinoline derivatives
CN1918166A (zh) 烟碱乙酰胆碱受体配体
CN1124266C (zh) 氮杂环辛烷和庚烷衍生物、其制备方法和治疗用途
CN1882584A (zh) 4－取代的咪唑
CN1914200A (zh) 烟碱性乙酰胆碱受体配件
KR20200029393A (ko) 오렉신 수용체 길항제
CN1914201A (zh) 烟碱乙酰胆碱受体配体
CN100445285C (zh) 烟碱性乙酰胆碱受体配体
CN101044144A (zh) 作为胆碱能配体的新的二氮杂双环芳基衍生物
HK1099652A (en) Nicotinic acetylcholine receptor ligands
JP2007511602A (ja) ５−置換イミダゾール類

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication